Comparative evaluation of the perioperative anesthesia methods for cancer patients undergoing pancreaticoduodenectomy

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

BACKGROUND: Pancreatoduodenal resections are one of the most traumatic and technically complex interventions in abdominal surgery. The correct anesthetic management and pain relief allow to substantially reduce the risk of perioperative complications, which remains high even in high-volume oncology centers with extensive experience. Finding new components and methods of anesthesia combined with evaluation of their effectiveness and safety remains a pressing issue.

AIM: To evaluate the efficacy and safety of using intravenous lidocaine infusion as a component of anesthesia and postoperative analgesia in cancer patients during pancreatoduodenal resection.

MATERIALS AND METHODS: We analyzed the course of anesthesia, operation and postoperative period of 43 patients (mean age 63.2±7.1 years) undergoing pancreaticoduodenectomy. For the purposes of the study, patients were randomly divided into 2 groups, based on anesthesia method: for the first group (n=19) we used epidural analgesia as a component of perioperative anesthesia, for the second group (n=24) we used prolonged intravenous infusion of lidocaine at an average dose of 1 mg/(kg×h). We analyzed the severity of pain syndrome according to Numeric rating scale for pain in postoperative period, as well as opioid requirement, the time of gastrointestinal function recovery, and post-operative complications frequency. In order to prevent systemic toxicity, drug monitoring was carried out — the determination of the plasma concentration of lidocaine.

RESULTS: Perioperative opioid requirement was comparable between groups, with no statistically significant differences observed. The degree of pain syndrome according to the Numeric rating scale for pain did not differ statistically, except for the number of points during activation on day 3: 4.00 (95% confidence interval 3.49–4.51) for epidural analgesia group, compared to 3.12 (95% confidence interval 2.64–3.61) for lidocaine infusion group, p=0.014. There was also a statistically significant increase in infusion volume for epidural analgesia group compared to lidocaine infusion group [8.83 ml/(kg×h) (Q1=7.90; Q3=10.06) and 7.33 ml/(kg×h) (Q1=6.28–Q3=8.49) respectively, p=0.034], as well as a greater need for intraoperative vasopressor support among the patients [15 (78.9%) and 10 (43.5%) respectively, p=0.029]. In the lidocaine group, the time to onset of peristalsis was significantly shorter than in the epidural analgesia group [median 48.0 h (Q1=48.00; Q3=72.00) compared to median 60.0 h (Q1=36.00; Q3=64.50) respectively, p=0.042]. The frequency of postoperative complications did not differ between the groups.

CONCLUSION: Based on a comparative analysis of the study results, it can be concluded that prolonged intravenous infusion of lidocaine, as a component of perioperative anesthetic protection during pancreatoduodenal resections, is safe and comparable in terms of analgesic efficacy to epidural blockade.

About the authors

Iuliia S. Zakharenkova

P. Hertsen Moscow Oncology Research Institute

Author for correspondence.
Email: juli_panch@mail.ru
ORCID iD: 0000-0001-6680-9847
Russian Federation, Moscow

Victoria E. Khoronenko

P. Hertsen Moscow Oncology Research Institute; Peoples' Friendship University of Russia

Email: khoronenko_mnioi@mail.ru
ORCID iD: 0000-0001-8845-9913

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow; Moscow

Vladimir S. Trifanov

P. Hertsen Moscow Oncology Research Institute

Email: trifan1975@yandex.ru
ORCID iD: 0000-0003-1879-6978

MD, Dr. Sci. (Medicine), Assistant Professor

Russian Federation, Moscow

References

  1. Ilic I, Ilic M. International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: A joinpoint regression analysis. World J Gastroenterol. 2022;28(32):4698–4715. doi: 10.3748/wjg.v28.i32.4698
  2. Cancer Incidence in Five Continents, CI5plus [Internet]. IARC CancerBase. c1965-2024 [cited 2020 Feb 7]. Available from: https://ci5.iarc.fr/ci5plus
  3. Kaprin AD, Starinskii VV, Shakhzadova AO, editors. Malignant neoplasms in Russia in 2020 (morbidity and mortality). Moscow: P.A. Herzen MNIOI — branch of FGBU NMC Radiology of the Ministry of Health of Russia; 2021. (In Russ).
  4. D’Cruz JR, Misra S, Shamsudeen S. Pancreaticoduodenectomy. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
  5. Kosuri K, Muscarella P, Bekaii-Saab TS. Updates and controversies in the treatment of pancreatic cancer. Clin Adv Hematol Oncol. 2006;4(1):47–54.
  6. McPhee JT, Hill JS, Whalen GF, et al. Perioperative mortality for pancreatectomy: a national perspective. Ann Surg. 2007;246(2):246–253. doi: 10.1097/01.sla.0000259993.17350.3a
  7. Klotz R, Larmann J, Klose C, et al. Gastrointestinal Complications After Pancreatoduodenectomy With Epidural vs Patient-Controlled Intravenous Analgesia: A Randomized Clinical Trial. JAMA Surg. 2020;155(7):e200794. doi: 10.1001/jamasurg.2020.0794
  8. Pratt WB, Steinbrook RA, Maithel SK, et al. Epidural analgesia for pancreatoduodenectomy: a critical appraisal. J Gastrointest Surg. 2008;12(7):1207–1220. doi: 10.1007/s11605-008-0467-1
  9. Kooij FO, Schlack WS, Preckel B, Hollmann MW. Does regional analgesia for major surgery improve outcome? Focus on epidural analgesia. Anesth Analg. 2014;119(3):740–744. doi: 10.1213/ANE.0000000000000245
  10. Cooke C, Kennedy ED, Foo I, et al. Meta-analysis of the effect of perioperative intravenous lidocaine on return of gastrointestinal function after colorectal surgery. Tech Coloproctol. 2019;23(1):15–24. doi: 10.1007/s10151-019-1927-1
  11. Wei S, Yu-Han Z, Wei-Wei J, Hai Y. The effects of intravenous lidocaine on wound pain and gastrointestinal function recovery after laparoscopic colorectal surgery. Int Wound J. 2020;17(2):351–362. doi: 10.1111/iwj.13279
  12. Ovechkin AM, Becker AA. Intravenous lidocaine infusion as a perspective component of multimodal analgesia, which affects on early postoperative outcome. Regional Anesthesia and Acute Pain Management. 2017;11(2). EDN: YUFIDT doi: 10.18821/1993-6508-2017-11-2-73-83
  13. Groen JV, Slotboom DEF, Vuyk J, et al. Epidural and Non-epidural Analgesia in Patients Undergoing Open Pancreatectomy: a Retrospective Cohort Study. J Gastrointest Surg. 2019;23:2439–2448. doi: 10.1007/s11605-019-04136-w
  14. Freise H, Van Aken HK. Risks and benefits of thoracic epidural anaesthesia. Br J Anaesth. 2011;107(6):859–868. doi: 10.1093/bja/aer339
  15. Werawatganon T, Charuluxanun S. Patient controlled intravenous opioid analgesia versus continuous epidural analgesia for pain after intra-abdominal surgery. Cochrane Database Syst Rev. 2005;1:CD004088. doi: 10.1002/14651858.CD004088.pub2
  16. Amini N, Kim Y, Hyder O, et al. A nationwide analysis of the use and outcomes of perioperative epidural analgesia in patients undergoing hepatic and pancreatic surgery. Am J Surg. 2015;210(3):483–491. doi: 10.1016/j.amjsurg.2015.04.009
  17. Choi DX, Schoeniger LO. For patients undergoing pancreatoduodenectomy, epidural anesthesia and analgesia improves pain but increases rates of intensive care unit admissions and alterations in analgesics. Pancreas. 2010;39(4):492–497. doi: 10.1097/MPA.0b013e3181bdfc76
  18. Sugimoto M, Nesbit L, Barton JG, et al. Epidural anesthesia dysfunction is associated with postoperative complications after pancreatectomy. J Hepatobiliary Pancreat Sci. 2016;23(2):102–109. doi: 10.1002/jhbp.307
  19. Wei S, Yu-Han Z, Wei-Wei J, Hai Y. The effects of intravenous lidocaine on wound pain and gastrointestinal function recovery after laparoscopic colorectal surgery. Int Wound J. 2020;17(2):351–362. doi: 10.1111/iwj.13279
  20. Axelrod TM, Mendez BM, Abood GJ, et al. Peri-operative epidural may not be the preferred form of analgesia in select patients undergoing pancreaticoduodenectomy. J Surg Oncol. 2015;111(3):306–310. doi: 10.1002/jso.23815
  21. Jamjittrong S, Matsuda A, Matsumoto S, et al. Postoperative non-steroidal anti-inflammatory drugs and anastomotic leakage after gastrointestinalу anastomoses: Systematic review and meta-analysis. Ann Gastroenterol Surg. 2019;4(1):64–75. doi: 10.1002/ags3.12300
  22. Varga Z, Sabzwari SRA, Vargova V. Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue. Cureus. 2017;9(4):e1144. doi: 10.7759/cureus.1144
  23. Weibel S, Jelting Y, Pace NL, et al. Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adults. Cochrane Database Syst Rev. 2018;6:Cd009642. doi: 10.1002/14651858
  24. Beaussier M, Delbos A, Maurice-Szamburski A, Ecoffey C, Mercadal L. Perioperative Use of Intravenous Lidocaine. Drugs. 2018;78(12):1229–1246. doi: 10.1007/s40265-018-0955-x
  25. Vigneault L, Turgeon AF, Lauzier F, et al. Perioperative intravenous lidocaine infusion for postoperative pain control: a meta-analysis of randomized controlled trials. Can J Anaesth. 2011;58:22–37. doi: 10.1007/s12630-010-9407-0
  26. Ventham NT, Kennedy ED, Brady RR, et al. Efficacy of intravenous lidocaine for postoperative analgesia following laparoscopic surgery: a meta-analysis. World J Surg. 2015;39:2220–2234. doi: 10.1007/s00268-015-3105-6
  27. Usubiaga JE, Wikinski J, Ferrero R, et al. Local anesthetic-induced convulsions in man — an electroencephalographic study. Anesth Analg. 1966;45:611–620.
  28. Drayer DE, Lorenzo B, Werns S, et al. Plasma levels, protein binding, and elimination data of lidocaine and active metabolites in cardiac patients of various ages. Clin Pharmacol Ther. 1983;34:14–22. doi: 10.1038/clpt.1983.122
  29. Weinberg L, Peake B, Tan C, Nikfarjam M. Pharmacokinetics and pharmacodynamics of lignocaine: a review. World J Anesthesiol. 2015;4:17–29. doi: 10.5313/wja.v4.i2.17
  30. Terkawi AS, Tsang S, Kazemi A, et al. A Clinical Comparison of Intravenous and Epidural Local Anesthetic for Major Abdominal Surgery. Regional Anesthesia & Pain Medicine. 2016;41(1):28–36. doi: 10.1097/AAP.0000000000000332
  31. Ho MLJ, Kerr SJ, Stevens J. Intravenous lidocaine infusions for 48 hours in open colorectal surgery: a prospective, randomized, double-blinded, placebo-controlled trial. Korean Journal of Anesthesiology. 2018;71(1):57–65. doi: 10.4097/kjae.2018.71.1.57
  32. Tejedor A, Bijelic L, Polanco M, Pujol E. Intravenous lidocaine infusion compared to thoracic epidural analgesia in cytoreductive surgery with or without heated intraperitoneal chemotherapy. A retrospective case-cohort study. Eur J Surg Oncol. 2023;49(3):597–603. doi: 10.1016/j.ejso.2022.11.096
  33. Han IW, Kim H, Heo JS, et al. Excess intraoperative fluid volume administration is associated with pancreatic fistula after pancreaticoduodenectomy: A retrospective multicenter study. Medicine. 2017;96(22):e6893. doi: 10.1097/MD.0000000000006893
  34. Gilgien J, Hübner M, Halkic N, et al. Perioperative fluids and complications after pancreatoduodenectomy within an enhanced recovery pathway. Sci Rep. 2020;21(10(1)):17898. doi: 10.1038/s41598-020-74907-y
  35. Weinberg L, Wong D, Karalapillai D, et al. The impact of fluid intervention on complications and length of hospital stay after pancreaticoduodenectomy (Whipple’s procedure). BMC Anesthesiol. 2014;14(35):1471–2253. doi: 10.1186/1471-2253-14-35
  36. Kulemann B, Fritz M, Glatz T, et al. Complications after pancreaticoduodenectomy are associated with higher amounts of intra- and postoperative fluid therapy: A single center retrospective cohort study. Ann Med Surg (Lond). 2017;16:23–29. doi: 10.1016/j.amsu.2017.02.042
  37. Eng OS, Goswami J, Moore D, et al. Intraoperative fluid administration is associated with perioperative outcomes in pancreaticoduodenectomy: a single center retrospective analysis. J Surg Oncol. 2013;108(4):242–247. doi: 10.1002/jso.23393
  38. Healy MA, McCahill LE, Chung M, et al. Intraoperative Fluid Resuscitation Strategies in Pancreatectomy: Results from 38 Hospitals in Michigan. Ann Surg Oncol. 2016;23(9):3047–3055. doi: 10.1245/s10434-016-5235-y
  39. Bragg D, El-Sharkawy A, Psaltis E, et al. Postoperative ileus: Recent developments in pathophysiology and management. Clinical Nutrition. 2015;34(3):367–376. doi: 10.1016/j.clnu.2015.01.016
  40. Sommer NP, Schneider R, Wehner S, et al. State-of-the-art colorectal disease: postoperative ileus. Int J Colorectal Dis. 2021;36:2017–2025. doi: 10.1007/s00384-021-03939-1
  41. Doudakmanis C, Bouliaris K, Kolla C, et al. Bacterial translocation in patients undergoing major gastrointestinal surgery and its role in postoperative sepsis. World J Gastrointest Pathophysiol. 2021;12(6):106–114. doi: 10.4291/wjgp.v12.i6.106
  42. Guay J, Nishimori M, Kopp SL. Epidural Local Anesthetics Versus Opioid-Based Analgesic Regimens for Postoperative Gastrointestinal Paralysis, Vomiting, and Pain After Abdominal Surgery: A Cochrane Review. Anesth Analg. 2016;123(6):1591–1602. doi: 10.1213/ANE.0000000000001628
  43. Shi WZ, Miao YL, Yakoob MY, et al. Recovery of gastrointestinal function with thoracic epidural vs. systemic analgesia following gastrointestinal surgery. Acta Anaesthesiol Scand. 2014;58(8):923–932. doi: 10.1111/aas.12375
  44. Pesco J, Young K, Nealon K, et al. Use and Outcomes of Epidural Analgesia in Upper Gastrointestinal Tract Cancer Resections. J Surg Res. 2021;257:433–441. doi: 10.1016/j.jss.2020.08.018
  45. Sholin IY, Avetisyan VA, Ezugbaia BS, et al. The use of lidocaine infusion for analgesia and prevention of ileus after major abdominal surgeries. Regional Anesthesia and Acute Pain Management. 2018;12(2):107–112. EDN: XXIHXV doi: 10.18821/1993-6508-2018-12-2-107-112
  46. Swenson BR, Gottschalk A, Wells LT, et al. Intravenous lidocaine is as effective as epidural bupivacaine in reducing ileus duration, hospital stay, and pain after open colon resection: a randomized clinical trial. Reg Anesth Pain Med. 2010;35(4). doi: 10.1097/AAP.0b013e3181e8d5da

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2023 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».